Literature DB >> 31447055

The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry.

Maria L Gonzalez Suarez1, Pingchuan Zhang2, Samih H Nasr2, Insara Jaffer Sathick3, Wonngarm Kittanamongkolchai3, Paul J Kurtin4, Mariam P Alexander2, Lynn D Cornell2, Mary E Fidler2, Joseph P Grande2, Loren P Herrera Hernandez2, Samar M Said2, Sanjeev Sethi2, Angela Dispenzieri5, Morie A Gertz5, Nelson Leung6.   

Abstract

Immunoglobulin light chain amyloidosis is the most frequent type of renal amyloidosis in the United States, accounting for 81% of cases. Accurate typing is crucial for early diagnosis and treatment of immunoglobulin-derived amyloidosis and to avoid treating other amyloidoses with potentially toxic chemotherapy. Immunofluorescence is the first step to type renal immunoglobulin-derived amyloidosis but the performance characteristics of this method are largely unknown. Here, we establish the sensitivity and specificity of immunofluorescence for diagnosing immunoglobulin-derived amyloidosis in patients whose amyloid typing was performed by the current gold standard of laser microdissection/mass spectrometry. Renal biopsy pathology reports originating from several institutions with a diagnosis of amyloidosis and which had amyloid typing by laser microdissection/mass spectrometry performed at our center were reviewed. Reported immunofluorescence staining for kappa or lambda of 2+ or more, with weak or no staining for the other light chain was considered positive for light chain amyloidosis by immunofluorescence. Based on microdissection/mass spectrometry results, of the 170 cases reviewed, 104 cases were typed as immunoglobulin-derived amyloidosis and 66 were typed as non-immunoglobulin-derived amyloidosis. Immunofluorescence sensitivity for diagnosing immunoglobulin-derived amyloidosis was 84.6%. The remaining 16 cases could not be diagnosed by immunofluorescence due to reported weak staining for all antigens or reported lack of preferential staining for one antigen. Immunofluorescence specificity was 92.4%. Five cases, all amyloid A amyloidosis, were misdiagnosed as immunoglobulin-derived amyloidosis by immunofluorescence. Immunofluorescence failed to accurately differentiate immunoglobulin-derived from non-immunoglobulin-derived amyloidosis in 12.3% of cases of renal amyloidosis. Relying on immunofluorescence alone for determining immunoglobulin-derived vs. non-immunoglobulin-derived amyloidosis may lead to misdiagnosis. Thus, immunofluorescence has inferior sensitivity and specificity compared with laser microdissection/mass spectrometry in the typing of immunoglobulin-derived amyloidosis.
Copyright © 2019 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  immunofluorescence; mass spectrometry; renal amyloidosis

Mesh:

Year:  2019        PMID: 31447055     DOI: 10.1016/j.kint.2019.05.027

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  4 in total

1.  Tandem Mass Spectrometry-Based Amyloid Typing Using Manual Microdissection and Open-Source Data Processing.

Authors:  William S Phipps; Kelly D Smith; Han-Yin Yang; Clark M Henderson; Hannah Pflaum; Melissa L Lerch; William E Fondrie; Michelle A Emrick; Christine C Wu; Michael J MacCoss; William S Noble; Andrew N Hoofnagle
Journal:  Am J Clin Pathol       Date:  2022-05-04       Impact factor: 5.400

2.  The Clinical Impact of Proteomics in Amyloid Typing.

Authors:  Michelle M Hill; Surendra Dasari; Peter Mollee; Giampaolo Merlini; Catherine E Costello; Bouke P C Hazenberg; Martha Grogan; Angela Dispenzieri; Morie A Gertz; Taxiarchis Kourelis; Ellen D McPhail
Journal:  Mayo Clin Proc       Date:  2021-04-09       Impact factor: 11.104

3.  AL-Kappa Primary Amyloidosis with Apolipoprotein A-IV Deposition.

Authors:  Akira Ishimitsu; Akihiro Tojo; Jun Hirao; Shohei Yokoyama; Takehiro Ohira; Yoshiki Murayama; Toshihiko Ishimitsu; Dedong Kang; Kazuho Honda; Takashi Ehara; Kazuyuki Ishida; Yoshihiko Ueda
Journal:  Intern Med       Date:  2022-03-15       Impact factor: 1.271

Review 4.  Renal amyloidosis: a new time for a complete diagnosis.

Authors:  V A Feitosa; P D M M Neves; L B Jorge; I L Noronha; L F Onuchic
Journal:  Braz J Med Biol Res       Date:  2022-10-03       Impact factor: 2.904

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.